Portage Biotech Inc Cash Flow Conversion Efficiency
Portage Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Portage Biotech Inc (PRTG) has a cash flow conversion efficiency ratio of -2.245x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.56 Million) by net assets ($695.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Portage Biotech Inc (1998–2025)
Cash flow conversion efficiency of Portage Biotech Inc from 1998 to 2025. This chart illustrates how Portage Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Portage Biotech Inc stock price today for real-time trading data and today's change.
Portage Biotech Inc Cash Flow Conversion Ratio Explained
Portage Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Portage Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Portage Biotech Inc ranked by their cash flow conversion efficiency. Also see PRTG company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cahayaputra Asa Keramik Tbk PT
JK:CAKK
|
0.138x |
|
Wave Entertainment Public Company Limited
BK:WAVE
|
0.054x |
|
Esthetics International Group
KLSE:5081
|
0.079x |
|
Zantat Holdings Berhad
KLSE:0301
|
0.023x |
|
Putra Rajawali Kencana PT
JK:PURA
|
0.012x |
|
Seyitler Kimya Sanayi AS
IS:SEYKM
|
0.049x |
|
Sky Quarry Inc
NASDAQ:SKYQ
|
-0.295x |
|
Brimstone Investment Corporation Ltd
JSE:BRT
|
0.023x |
Annual Cash Flow Conversion Efficiency for Portage Biotech Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Portage Biotech Inc from 1998 to 2025. Review Portage Biotech Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $-827.00K | $-5.46 Million | 6.605x | +253.79% |
| 2024-03-31 | $3.33 Million | $-14.30 Million | -4.295x | -2582.00% |
| 2023-03-31 | $75.39 Million | $-12.07 Million | -0.160x | -291.65% |
| 2022-03-31 | $165.43 Million | $-6.76 Million | -0.041x | -40.87% |
| 2021-03-31 | $147.60 Million | $-4.28 Million | -0.029x | -13.81% |
| 2020-03-31 | $145.64 Million | $-3.71 Million | -0.026x | -341.53% |
| 2019-03-31 | $148.56 Million | $-858.00K | -0.006x | +94.82% |
| 2018-03-31 | $9.62 Million | $-1.07 Million | -0.112x | -403.20% |
| 2017-03-31 | $59.59 Million | $-1.32 Million | -0.022x | +95.32% |
| 2016-03-31 | $12.33 Million | $-5.84 Million | -0.474x | +25.43% |
| 2015-03-31 | $4.12 Million | $-2.61 Million | -0.635x | -66.43% |
| 2014-03-31 | $5.07 Million | $-1.94 Million | -0.382x | +36.44% |
| 2013-03-31 | $2.98 Million | $-1.79 Million | -0.600x | -117.39% |
| 2012-03-31 | $4.85 Million | $-1.34 Million | -0.276x | +5.92% |
| 2011-03-31 | $8.94 Million | $-2.62 Million | -0.294x | -457.97% |
| 2010-03-31 | $6.77 Million | $-356.14K | -0.053x | +79.11% |
| 2009-03-31 | $1.14 Million | $-287.38K | -0.252x | -170.28% |
| 2008-03-31 | $5.03 Million | $-468.92K | -0.093x | -16.61% |
| 2007-03-31 | $5.74 Million | $-458.84K | -0.080x | +43.87% |
| 2006-03-31 | $4.53 Million | $-645.50K | -0.142x | +25.05% |
| 2004-03-31 | $1.69 Million | $-321.51K | -0.190x | -127.71% |
| 2003-03-31 | $-214.26K | $-146.90K | 0.686x | +101.34% |
| 2002-03-31 | $3.06K | $-156.80K | -51.310x | -7026.10% |
| 2001-03-31 | $481.93K | $-347.00K | -0.720x | -146.59% |
| 2000-03-31 | $1.60 Million | $-466.90K | -0.292x | +90.95% |
| 1999-03-31 | $106.97K | $-345.09K | -3.226x | -445.75% |
| 1998-03-31 | $-453.32K | $-422.97K | 0.933x | -- |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more